Literature DB >> 8664375

Activation of the radiosensitive EGR-1 promoter induces expression of the herpes simplex virus thymidine kinase gene and sensitivity of human glioma cells to ganciclovir.

T Joki1, M Nakamura, T Ohno.   

Abstract

Herein we describe experiments showing that the early growth response gene 1 (EGR-1) promoter is sufficient to confer selective expression of the luciferase gene (Luc) in glioma cell lines exposed to ionizing radiation. Activity of the EGR-1 promoter was investigated in human glioblastoma cells using the plasmid vector, pEGR-Luc. The EGR-1 promoter gene directed radiosensitive expression of luciferase. This promoter showed high levels of activity (10-fold) in irradiated glioma cell lines as compared to basal levels of activity in nonirradiated cell lines. Maximum activation was detectable at 1-3 hr after stimulation with 20 Gy. The results also demonstrate that cells modified to contain the herpes simplex virus-thymidine kinase (HSV-tk) gene under control of the EGR-1 promoter become sensitive to treatment with the antiviral agent ganciclovir (GCV), whereas nonirradiated cells and nontransfected cells were unaffected by this agent. This results suggest that therapeutic genes can be expressed selectively in irradiated glioma cells. The results also indicate that the EGR-1 promoter can be used to induce exogenous genes selectively in radiation fields used for the treatment of malignant brain tumors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8664375     DOI: 10.1089/hum.1995.6.12-1507

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  11 in total

1.  Cancer gene therapy: combination with radiation therapy and the role of bystander cell killing in the anti-tumor effect.

Authors:  Katalin Lumniczky; Géza Sáfrány
Journal:  Pathol Oncol Res       Date:  2006-06-24       Impact factor: 3.201

Review 2.  Targeted vectors for gene therapy of cancer and retroviral infections.

Authors:  W Walther; U Stein
Journal:  Mol Biotechnol       Date:  1996-12       Impact factor: 2.695

3.  Demonstration of Tightly Radiation-Controlled Molecular Switch Based on CArG Repeats by In Vivo Molecular Imaging.

Authors:  Ya-Ju Hsieh; Luen Hwu; Chien-Chih Ke; Ai-Lin Huang; Fu-Du Chen; Shyh-Jong Wu; Sharon Chia-Ju Chen; Yong-Hua Zhao; Ren-Shyan Liu
Journal:  Mol Imaging Biol       Date:  2015-12       Impact factor: 3.488

Review 4.  Chapter seven--Cancer treatment with gene therapy and radiation therapy.

Authors:  Sergey A Kaliberov; Donald J Buchsbaum
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

Review 5.  Molecular chemotherapy for breast cancer.

Authors:  A Patterson; A L Harris
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

6.  Radiation-inducible silencing of uPA and uPAR in vitro and in vivo in meningioma.

Authors:  Venkateswara Rao Gogineni; Arun Kumar Nalla; Reshu Gupta; Bharathi Gorantla; Meena Gujrati; Dzung H Dinh; Jasti S Rao
Journal:  Int J Oncol       Date:  2010-04       Impact factor: 5.650

7.  Inducible promoters for gene therapy of head and neck cancer: an in vitro study.

Authors:  Marianne Schmidt; Tonja Heimberger; Petra Gruensfelder; Gabriele Schler; Florian Hoppe
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-08-12       Impact factor: 2.503

8.  p53 activated by AND gate genetic circuit under radiation and hypoxia for targeted cancer gene therapy.

Authors:  Miao Ding; Rong Li; Rong He; Xingyong Wang; Qijian Yi; Weidong Wang
Journal:  Cancer Sci       Date:  2015-09       Impact factor: 6.716

9.  CArG-driven GADD45α activated by resveratrol inhibits lung cancer cells.

Authors:  Qiwen Shi; Werner Geldenhuys; Vijaykumar Sutariya; Anupam Bishayee; Isha Patel; Deepak Bhatia
Journal:  Genes Cancer       Date:  2015-05

10.  Transcriptional Targeting in Cancer Gene Therapy.

Authors:  Tracy Robson; David G. Hirst
Journal:  J Biomed Biotechnol       Date:  2003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.